INDUSTRY-ACADEMIC COOPERATION FOUNDATION; YONSEI UNIVERSITY
发明人:
PARK, Tae Sun,WHANG, Wan Kyunn
申请号：
KRKR2013/002668
公开号：
WO2013/147561A1
申请日:
2013.03.30
申请国别(地区):
WO
年份:
2013
代理人:
摘要：
The present invention provides a pharmaceutical composition for preventing or treating a metabolic disease, comprising an extract from Smilax chinaLinne as an active ingredient wherein the metabolic disease is selected from the group consisting of obesity, hyperlipidemia and fatty liver. The present invention results in decreases of gene expressions of major transcription factors LXRa and SREBP1-C, which play an important role in decrease of body fats, decrease of visceral fats and adipogenesis, and their target genes CD36 and aP2, whereby the present invention exhibits effects for preventing or treating obesity. The present composition improves fat accumulation in liver tissue by decreasing lipid levels in liver tissue such that it has effects for preventing or treating fatty liver. The present composition provides a food composition for improving or alleviating a metabolic disease, comprising an extract from Smilax china Linne as an active ingredient wherein the metabolic disease is selected from the group consisting of obesity, hyperlipidemia and fatty liver. In addition, the present composition provides a method for preventing or treating a metabolic disease, comprising administering to a subject in need thereof a therapeutically effective amount of a composition comprising an extract from Smilax china Linne as an active ingredient wherein the metabolic disease is selected from the group consisting of obesity, hyperlipidemia and fatty liver.La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement dune maladie métabolique, comprenant un extrait de Smilax china Linne comme principe actif dans laquelle la maladie métabolique est choisie dans le groupe constitué par lobésité, lhyperlipidémie et la stéatose du foie. La présente invention permet dobtenir des diminutions de facteurs de transcription majeure des expressions génétiques de LXRa et SREBP1-C, qui jouent un rôle important dans la réduction de graisses du corps, la dim
